Daily application of roflumilast cream for 52 weeks improves the signs and symptoms of AD in patients with various comorbid atopic conditions.

Study met the primary endpoint and all secondary endpoints, highly consistent with rapid response from the INTEGUMENT-1 and INTEGUMENT-2 pivotal trials For the primary endpoint, 25.4% of children ...

58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4 Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a ...

Full data results will be presented at future medical conferences and in peer-reviewed journals. The INTEGUMENT-1 study met the primary endpoint and all secondary endpoints. Topline results were ...

Roflumilast cream 0.05% showed durable efficacy and long-term tolerability in children aged 2 to 5 years with atopic dermatitis over 56 weeks. The cream demonstrated high application-site tolerability ...

Arcutis Biotherapeutics has announced promising results from its Phase 3 INTEGUMENT-OLE study concerning the investigational ZORYVE cream for treating atopic dermatitis (AD). The long-term study ...

Today, the FDA approved roflumilast cream 0.15% (Zorvye; Arcutis Biotherapeutics) for the treatment of mild to moderate atopic dermatitis in patients 6 years and older. Roflumilast cream 0.15% is a ...